Societe Generale’s Juno Therapeutics, Inc. JUNO Stock Holding History

Societe Generale’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$153K	Buy	+3,978	New	+$165K	﹤0.01%	2223

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Societe Generale's JUNO Position: Q2 2016 in Review

Societe Generale opened a new position in Juno Therapeutics, Inc. (JUNO) in Q2 2016: 3,978 shares worth $153K. The stake represents ﹤0.01% of the portfolio and ranks #2223 among its holdings.

170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

Societe Generale held 3,978 shares of Juno Therapeutics, Inc. worth $153K as of Q2 2016.
Juno Therapeutics, Inc. was a new Societe Generale position in Q2 2016.
Juno Therapeutics, Inc. made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2223 holding.
170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.